Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab in combination with paclitaxel, carboplatin and bevacizumab within its marketing authorisation for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy.
Following on from information provided to NICE by the company in September 2020 the appraisal of Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 2700
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2020 the appraisal of Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 July 2020 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual